Cycl2r,

I believe that many BPs must appreciate the utility of Leronlimab and the resultant disruption to their business from its approval resultant penetration into many markets.

I agree with your assessment, as smaller companies may be more willing to partner with a Cytodyn, rather than attempting to create a similar CCR5 antagonizing mAb and jump ahead of LL.

That being said, large BPs have the cash and may push for partnerships across multiple indications, to protect themselves from others partnering with Cytodyn amd eating their lunch.

Of course all conjecture, attempting to apply a rational assessment without any relevant experience.

Time will tell, but fingers crossed. We, Cytodyn and patients benefit when Leronlimab finally gets off the bench and into the game.